HT1080 (ATCC® CCL-121™) is a human fibrosarcoma cell line initiated from a 35-year-old Caucasian male. The cells are adherent with an epithelial morphology. Following implantation into immunocompromised mice, the cells form primary tumors and distant metastases.
*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.
HT1080 cells are suitable for in vitro and in vivo experimentation. Immunocompromised mice should be used for in life studies, and will form tumors and metastases following implantation of the cells.
The following chart provides some examples of HT1080 cells used as a xenograft model.
|Route of Implantation||Mice||Tumor/Metastases||References|
|Intramuscular||Nude||Primary tumor, lung metastases|
|Subcutaneous||Nude||Subcutaneous tumor, lung metastases, few liver and brain metastases|
|Mammary gland||Nude||Mammary tumor, lung metastases|
Stable reporter cell lines:
Our HT1080 reporter cell lines can be tracked in vivo, making them great tools for studying the mechanisms of tumor growth, as well as evaluating the effects of various drugs or therapies in animals. Our HT1080 cells are available with a variety of different reporters, including the human sodium iodide symporter (hNIS), firefly luciferase (Fluc), enhanced green fluorescent protein (eGFP), or near-infrared fluorescent protein (iRFP). Several dual reporter HT1080 cell lines are available to facilitate multi-modality imaging.
In order to ensure high, constitutive expression of the reporter proteins, our cell lines are generated by lentiviral vector transduction. The lentiviral vectors used for these transductions are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. This increases the biosafety of the lentiviral vectors by preventing mobilization of replication competent viruses (Miyoshi et al., J Virol. 1998).